View Past PerformanceGenolution バランスシートの健全性財務の健全性 基準チェック /56Genolutionの総株主資本は₩68.3B 、総負債は₩23.8Bで、負債比率は34.9%となります。総資産と総負債はそれぞれ₩94.3Bと₩26.0Bです。主要情報34.88%負債資本比率₩23.83b負債インタレスト・カバレッジ・レシオn/a現金₩27.57bエクイティ₩68.32b負債合計₩26.02b総資産₩94.35b財務の健全性に関する最新情報分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...すべての更新を表示Recent updatesNew Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 66% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 66% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩30.5b market cap, or US$20.2m).お知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering財務状況分析短期負債: A225220の 短期資産 ( ₩33.4B ) が 短期負債 ( ₩25.6B ) を超えています。長期負債: A225220の短期資産 ( ₩33.4B ) が 長期負債 ( ₩376.4M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: A225220総負債よりも多くの現金を保有しています。負債の削減: A225220の負債対資本比率が過去 5 年間で減少したかどうかを判断するにはデータが不十分です。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: A225220は、現在の フリーキャッシュフロー に基づき、3 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: A225220は、フリー キャッシュ フローが毎年8.6 % の歴史的成長率で成長し続ける場合、 1.9年間十分なキャッシュ ランウェイを有します。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/27 18:31終値2026/06/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genolution Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • May 30New major risk - Revenue and earnings growthEarnings have declined by 66% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 66% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩30.5b market cap, or US$20.2m).
お知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).
お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.
お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.
お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.
分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.
お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering